Galapagos (NASDAQ:GLPG) was upgraded by equities research analysts at Barclays from an “equal weight” rating to an “overweight” rating in a research report issued on Wednesday, Price Targets.com reports.
A number of other equities research analysts have also commented on the stock. UBS Group reaffirmed a “neutral” rating on shares of Galapagos in a research note on Monday. Bank of America raised shares of Galapagos from an “underperform” rating to a “neutral” rating and upped their price objective for the company from $93.00 to $94.00 in a research note on Tuesday, February 23rd. Morgan Stanley reduced their price objective on shares of Galapagos from $129.00 to $117.00 and set an “overweight” rating on the stock in a research note on Wednesday, March 17th. Raymond James raised shares of Galapagos from a “market perform” rating to an “outperform” rating and set a $100.00 price objective on the stock in a research note on Thursday, February 25th. Finally, Maxim Group lowered shares of Galapagos from a “buy” rating to a “hold” rating in a research note on Wednesday, February 10th. Two equities research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $150.08.
Shares of NASDAQ GLPG opened at $79.39 on Wednesday. Galapagos has a 52-week low of $74.51 and a 52-week high of $233.14. The firm has a 50 day moving average price of $80.60 and a two-hundred day moving average price of $105.88. The stock has a market cap of $5.20 billion, a P/E ratio of -12.03 and a beta of 0.76.
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes various small molecule medicines. Its clinical stage programs include filgotinib, a JAK1 inhibitor that is in various phases of clinical trials for the treatment of rheumatoid arthritis, Crohn's disease, ulcerative colitis, small bowel CD, fistulizing CD, ankylosing spondylitis, and psoriatic arthritis.
Read More: Return on Investment (ROI)
Receive News & Ratings for Galapagos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galapagos and related companies with MarketBeat.com's FREE daily email newsletter.